查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1274336

患者来源的异种移植模型全球市场研究报告-2023-2030 年行业分析、规模、份额、增长、趋势和预测

Global Patient-Derived Xenograft Model Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 154 Pages | 商品交期: 最快1-2个工作天内

价格

全球对患者来源的异种移植模型市场的需求将从2022年的3.3102亿美元增长到2030年的36.3467亿美元，预计2023-2030年调查期间的复合年增长率为34.92%。

近年来，患者来源的异种移植 (PDX) 模型备受关注。 这些模型的一般特征是将源自患者的肿瘤组织引入新鲜的免疫功能低下的小鼠中。 该模型用于临床前研究，以寻找治疗效果和治疗耐药性的生物标誌物，并追踪肿瘤生长对治疗的反应。 PDX 模型越来越被广泛认为是了解癌症特征、设计新治疗方法和预测治疗效果的有用工具。

市场动态：

推动患者来源的异种移植 (PDX) 模型市场扩张的主要原因之一是全球范围内对定制治疗的需求不断增长。 对个性化治疗的需求不断增长、公共和私人对癌症研究的持续支持以及製药行业加大研发力度是推动该市场扩张的主要因素。 为改进当前疗法而加大的研发力度正在进一步影响市场。 公共和商业部门对癌症研究的持续财政和经济支持将推动市场扩张。 然而，定制 PDX 模型的成本和使用动物模型进行癌症研究的严格规定可能会阻碍市场的发展。

这份研究报告描述了波特的五力模型、市场吸引力分析和价值链分析。 这些工具可帮助您清楚地了解您的行业结构并评估您在全球范围内的竞争吸引力。 此外，这些工具还能够全面评估全球患者来源的异种移植模型市场的各个细分市场。 患者来源的异种移植模型行业的发展和趋势为这项研究提供了一种整体方法。

市场细分：

患者来源的异种移植模型市场报告的这一部分提供了国家和地区层面的细分市场的详细数据，从而帮助战略制定者确定目标受众和他们各自产品或服务的即将到来的机会。以支持

按肿瘤类型

  • 肺癌
  • 胰腺癌
  • 前列腺癌
  • 乳腺癌
  • 其他癌症

按模型类型

  • 鼠标
  • 大鼠

由最终用户

  • 製药和生物製药公司
  • 学术和研究机构
  • CRO□CDMO

按地区分析：

本节介绍了区域前景，重点关注北美、欧洲、亚太地区、拉丁美洲、中东和非洲患者来源的异种移植模型市场的当前和未来需求。 此外，该报告重点关注所有主要地区每个单独应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况和全球竞争格局的详细视图。 患者来源的异种移植模型市场的主要参与者是 Charles River Laboratories、The Jackson Laboratory、Crown Bioscience、Altogen Labs、Envigo、WuXi AppTec、Oncodesign、Hera Biolabs、XenTech、Abnova Corp。战略发展，例如能力、合作伙伴关係、财务概览、协作、新产品开发和新产品发布。

如果您有定制要求，请联繫我们。 我们的研究团队可以根据您的需要提供定制报告。

内容

第一章前言

  • 本报告的内容
    • 目的
    • 目标受众
    • 独特的销售主张 (USP) 及其提供的内容
  • 调查范围
  • 调查方法
    • 市场调研过程
    • 市场研究方法

第 2 章执行摘要

  • 市场亮点
  • 全球市场概况

第 3 章患者来源的异种移植模型 - 行业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场製约因素
  • 市场机会
  • 行业趋势
  • 波特的五力分析
  • 市场吸引力分析
    • 按肿瘤类型进行的市场吸引力分析
    • 按模型类型进行市场吸引力分析
    • 按市场进行的吸引力分析：按最终用户
    • 市场吸引力分析：按地区

第四章价值链分析

  • 价值链分析
  • 原材料分析
    • 成分錶
    • 原材料製造商列表
    • 主要原材料价格走势
  • 潜在买家名单
  • 营销渠道
    • 直接营销
    • 间接营销
    • 营销渠道趋势

第 5 章 COVID-19 爆发的影响分析

第 6 章患者来源异种移植模型的全球市场分析（按肿瘤类型）

  • 肿瘤类型概述
  • 实际数据和预测数据
  • 按肿瘤类型分析
  • 肺癌
  • 胰腺癌
  • 前列腺癌
  • 乳腺癌
  • 其他癌症

第 7 章患者来源异种移植模型的全球市场分析：按模型类型分类

  • 按模型类型概述
  • 实际数据和预测数据
  • 按模型类型分析
  • 鼠标
  • 大鼠

第 8 章患者来源异种移植模型的全球市场销售分析：按最终用户分类

  • 最终用户总结
  • 实际数据和预测数据
  • 最终用户分析
  • 製药和生物製药公司
  • 学术和研究机构
  • CRO□CDMO

第 9 章患者来源异种移植模型的全球市场销售分析：按地区

  • 按地区进行的销售前景分析
  • 介绍销售分析
  • 北美销售分析
    • 概览、历史和预测销售分析
    • 北美各部门的销售分析
    • 北美销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史和预测销售分析
    • 按细分市场进行的欧洲销售分析
    • 按国家/地区划分的欧洲销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 意大利销售分析
    • 俄罗斯销售分析
    • 其他欧洲销售分析
  • 亚太地区销售分析
    • 概览、历史和未来销售分析
    • 亚太地区各部门的销售分析
    • 亚太国家/地区销售分析
    • 在中国的销售分析
    • 印度销售分析
    • 日本的销售分析
    • 韩国销售分析
    • 澳大利亚销售分析
    • 其他亚太地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史和未来销售分析
    • 拉丁美洲各部门的销售分析
    • 拉丁美洲国家/地区的销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利的销售分析
    • 其他拉丁美洲销售分析
  • 中东和非洲销售分析
    • 概览、历史和未来销售分析
    • 中东/非洲地区的销售分析
    • 中东和非洲国家/地区的销售分析
    • 沙特阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 其他中东和非洲销售分析

第10章患者来源异种移植模型公司的竞争状况

  • 人源异种移植模型市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第11章公司简介

  • 前 10 名公司的市场份额分析
  • 市场集中度
  • 查尔斯河实验室
    • 公司简介
    • 企业收入
    • 产品介绍
    • 近期发展状况
  • 杰克逊实验室
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期发展状况
  • 中冠生物科学
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期发展状况
  • 阿尔托金实验室
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期发展状况
  • 恩维戈
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期发展状况
  • 药明康德
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期发展状况
  • 肿瘤设计
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期发展状况
  • 赫拉生物实验室
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期发展状况
  • XenTech
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期发展状况
  • Abnova 公司
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期趋势

注意：公司简介中的财务细节和近期发展基于可用信息，可能不包括私营公司。

Product Code: VMR112110348

The global demand for Patient-Derived Xenograft Model Market is presumed to reach the market size of nearly USD 3634.67 MN by 2030 from USD 331.02 MN in 2022 with a CAGR of 34.92% under the study period 2023 - 2030.

Patient-derived Xenograft (PDX) models have gained attention in recent years. These models are typically characterized by introducing fresh immunodeficient mice with patient-derived tumour tissues. These models have been successfully utilized in preclinical investigations to find potential biomarkers for treatment response and resistance and to track tumours' growth in response to therapy. PDX models are becoming more widely acknowledged as a useful tool for determining the characteristics of cancer, coming up with new treatments, and foretelling the efficacy of therapies. 

Market Dynamics:

One of the key reasons promoting the expansion of the patient-derived xenograft (PDX) model market is the rising need for customized therapy on a global scale. The increasing need for personalized treatment, ongoing public and private support for cancer research, and an increase in R&D efforts in the pharmaceutical industry are the main factors propelling the expansion of this market. The increase in R&D efforts to improve the current treatment alternatives further impacts the market. Market expansion is accelerated by ongoing financial and economic assistance from the public and commercial sectors for cancer research. However, the cost of the customized PDX models and the strict regulations for utilizing animal models in cancer research may obstruct the market. 

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of patient-derived xenograft model. The growth and trends of patient-derived xenograft model industry provide a holistic approach to this study. 

Market Segmentation:

This section of the patient-derived xenograft model market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Tumor Type

  • Lung Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Breast Cancer
  • Other Cancer

By Model Type

  • Mice
  • Rats

By End-User

  • Pharmaceutical And Biopharmaceutical Companies
  • Academic & Research Institutes
  • CROs & CDMOs

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Patient-Derived Xenograft Model market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the patient-derived xenograft model market include Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . PATIENT-DERIVED XENOGRAFT MODEL - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Tumor Type
    • 3.7.2 Market Attractiveness Analysis By Model Type
    • 3.7.3 Market Attractiveness Analysis By End-user
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET ANALYSIS BY TUMOR TYPE

  • 6.1 Overview by Tumor Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Tumor Type
  • 6.4 Lung Cancer Historic and Forecast Sales by Regions
  • 6.5 Pancreatic Cancer Historic and Forecast Sales by Regions
  • 6.6 Prostate Cancer Historic and Forecast Sales by Regions
  • 6.7 Breast Cancer Historic and Forecast Sales by Regions
  • 6.8 Other Cancer Historic and Forecast Sales by Regions

7 . GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET ANALYSIS BY MODEL TYPE

  • 7.1 Overview by Model Type
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Model Type
  • 7.4 Mice Historic and Forecast Sales by Regions
  • 7.5 Rats Historic and Forecast Sales by Regions

8 . GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET SALES ANALYSIS BY END-USER

  • 8.1 Overview by End-user
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End-user
  • 8.4 Pharmaceutical And Biopharmaceutical Companies Historic and Forecast Sales by Regions
  • 8.5 Academic & Research Institutes Historic and Forecast Sales by Regions
  • 8.6 CROs & CDMOs Historic and Forecast Sales by Regions

9 . GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE PATIENT-DERIVED XENOGRAFT MODEL COMPANIES

  • 10.1. Patient-Derived Xenograft Model Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF PATIENT-DERIVED XENOGRAFT MODEL INDUSTRY

  • 11.1. Top 10 Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Charles River Laboratories
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. The Jackson Laboratory
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Crown Bioscience
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. Altogen Labs
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Envigo
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. WuXi AppTec
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Oncodesign
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Hera Biolabs
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. XenTech
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Abnova Corp.
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Tumor Type (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Pancreatic Cancer Market Sales by Geography (USD MN)
  • Prostate Cancer Market Sales by Geography (USD MN)
  • Breast Cancer Market Sales by Geography (USD MN)
  • Other Cancer Market Sales by Geography (USD MN)
  • Analysis Market by Model Type (USD MN)
  • Mice Market Sales by Geography (USD MN)
  • Rats Market Sales by Geography (USD MN)
  • Analysis by End-user (USD MN)
  • Pharmaceutical And Biopharmaceutical Companies Market Sales by Geography (USD MN)
  • Academic & Research Institutes Market Sales by Geography (USD MN)
  • CROs & CDMOs Market Sales by Geography (USD MN)
  • Global Patient-Derived Xenograft Model Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Patient-Derived Xenograft Model Report
  • Market Research Process
  • Market Research Methodology
  • Global Patient-Derived Xenograft Model Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Tumor Type
  • Market Attractiveness Analysis by Model Type
  • Market Attractiveness Analysis by End-user
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Tumor Type (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Pancreatic Cancer Market Sales by Geography (USD MN)
  • Prostate Cancer Market Sales by Geography (USD MN)
  • Breast Cancer Market Sales by Geography (USD MN)
  • Other Cancer Market Sales by Geography (USD MN)
  • Global Market Analysis by Model Type (USD MN)
  • Mice Market Sales by Geography (USD MN)
  • Rats Market Sales by Geography (USD MN)
  • Global Market Analysis by End-user (USD MN)
  • Pharmaceutical And Biopharmaceutical Companies Market Sales by Geography (USD MN)
  • Academic & Research Institutes Market Sales by Geography (USD MN)
  • CROs & CDMOs Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.